中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)  

Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer(2020 Version)

作　　者：周彩存[1] 王洁 王宝成[3] 程颖[4] 王哲海[5] 韩宝惠[6] 卢铀[7] 伍钢[8] 张力[9] 宋勇 朱波[11] 胡毅[12] 王子平 宋启斌[14] 任胜祥[1] 何雅億[1] 胡晓桦[15] 张艰[16] 姚煜[17] 赵洪云[18] 王志杰 褚倩[19] 段建春 柳菁菁[4] 秦叔逵 Caicun ZHOU;Jie WANG;Baocheng WANG;Ying CHENG;Zhehai WANG;Baohui HAN;You LU;Gang WU;Li ZHANG;Yong SONG;Bo ZHU;Yi HU;Ziping WANG;Qibin SONG;Shengxiang REN;Yayi HE;Xiaohua HU;Jian ZHANG;Yu YAO;Hongyun ZHAO;Zhijie WANG;Qian CHU;Jianchun DUAN;Jingjing LIU;Shukui QIN(Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;No.960 Hospital of PLA,Jinan 250031,China;Jilin Cancer Hospital,Changchun 130012,China;Shandong Cancer Hospital and Institute,Jinan 250117,China;Shanghai Chest Hospital,Shanghai 200030,China;West China Hospital,Sichuan University,Chengdu 610041,China;Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Peking Union Medical College Hospital,Beijing 100010,China;General Hospital of Eastern Theater Command,Nanjing 210002,China;Xinqiao Hospital,The Army Medical University,Chongqing 400037,China;Chinese PLA General Hospital,Beijing 100853,China;Beijing Cancer Hospital,Beijing 100142,China;Renmin Hospital of Wuhan University,Wuhan 430060,China;The First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China;Xijing Hospital,Xi'an 710032,China;The First Affiliated Hospital of Xi’an Jiaotong University,Xi'an 710061,China;Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Cancer Center,Eastern Theater General Hospital of the Chinese PLA,Nanjing 210002,China)

机构地区：[1]同济大学附属上海市肺科医院,上海200433 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院&北京协和医学院肿瘤医院,北京100021 [3]中国人民解放军联勤保障部队第960医院,济南250031 [4]吉林省肿瘤医院,长春130012 [5]山东省肿瘤医院,济南250117 [6]上海市胸科医院,上海200030 [7]四川大学华西医院,成都610041 [8]华中科技大学同济医学院附属协和医院,武汉430022 [9]北京协和医院,北京100010 [10]东部战区总医院,南京210002 [11]重庆新桥医院,重庆400037 [12]中国人民解放军总医院,北京100853 [13]北京大学肿瘤医院,北京100142 [14]武汉大学人民医院,武汉430060 [15]广西医科大学第一附属医院,南宁530021 [16]西京医院,西安710032 [17]西安交通大学第一附属医院,西安710061 [18]中山大学肿瘤防治中心,广州510060 [19]华中科技大学同济医学院附属同济医院,武汉430030 [20]解放军东部战区总医院肿瘤中心,南京210002

出　　处：《中国肺癌杂志》2021年第4期217-235,共19页Chinese Journal of Lung Cancer

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)是肺癌最常见的病理类型。晚期NSCLC的系统性抗肿瘤治疗经历了化疗、靶向治疗及免疫治疗的变革,患者总体生存时间不断延长。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs),尤其是程序性死亡分子-1(programmed cell death protein 1,PD-1)/程序性死亡分子配体-1(programmed death-ligand 1,PD-L1)抗体已成为表皮生长因子受体(epidermal growth factor receptor,EGFR)/间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)阴性晚期NSCLC一线及二线的标准治疗和局部晚期NSCLC同步放化疗后标准治疗,并在辅助/新辅助治疗中显示出可喜的结果,改变了NSCLC整体治疗格局。随着越来越多的ICIs在国内获批肺癌适应证,中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)NSCLC专家委员会牵头,组织该领域的专家,结合2019年版专家共识,参考最新国内外文献、临床研究数据及系统评价,在专家共同讨论的基础上,达成统一意见并制定、更新本共识,为国内同行更好地应用ICIs治疗NSCLC提供参考意见。Non-small cell lung cancer(NSCLC)is the most common pathological type of lung cancer.The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy,targeted therapy and immunotherapy,which results in greatly improved survival for patients with advanced NSCLC.Immune checkpoint inhibitors(ICIs),especially targeting programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1),has changed the treatment paradigm of NSCLC.ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR)mutation or anaplastic lymphomakinase(ALK)translocation in the first-or second-line setting,and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy.ICIs are also promising in adjuvant/neoadjuvant therapy.More and more ICIs have been approved domestically for the treatment of NSCLC.Led by the NSCLC expert committee of Chinese Society of Clinical Oncology(CSCO),this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures,clinical trial data,systematic reviews,experts’discussion and the consensus(2019 version).This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs.

关 键 词：肺肿瘤 免疫治疗 程序性死亡分子-1/程序性死亡分子配体-1 专家共识 

分 类 号：R734.2[医药卫生—肿瘤]